SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

NCT05498636 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

67

Enrollment

OTHER

Sponsor class

Conditions

DLBCL

Interventions

COMBINATION_PRODUCT: Selinexor combined with Prednisone, Etoposide, and Lenalidomide

Sponsor

The Affiliated Hospital of Qingdao University